SG11201405942RA - Substituted pyridopyrimidine compounds and their use as flt3 inhibitors - Google Patents

Substituted pyridopyrimidine compounds and their use as flt3 inhibitors

Info

Publication number
SG11201405942RA
SG11201405942RA SG11201405942RA SG11201405942RA SG11201405942RA SG 11201405942R A SG11201405942R A SG 11201405942RA SG 11201405942R A SG11201405942R A SG 11201405942RA SG 11201405942R A SG11201405942R A SG 11201405942RA SG 11201405942R A SG11201405942R A SG 11201405942RA
Authority
SG
Singapore
Prior art keywords
flt3 inhibitors
substituted pyridopyrimidine
pyridopyrimidine compounds
compounds
substituted
Prior art date
Application number
SG11201405942RA
Inventor
Hong Woo Kim
Hee Kyu Lee
Ho-Juhn Song
Jaekyoo Lee
Jong Sung Koh
Youngsam Kim
Jung-Ho Kim
Se Won Kim
In Yong Lee
Original Assignee
Genosco
Oscotec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genosco, Oscotec Inc filed Critical Genosco
Publication of SG11201405942RA publication Critical patent/SG11201405942RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/305Mercury compounds
    • A61K31/31Mercury compounds containing nitrogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11201405942RA 2012-03-22 2013-03-15 Substituted pyridopyrimidine compounds and their use as flt3 inhibitors SG11201405942RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261614274P 2012-03-22 2012-03-22
PCT/US2013/032575 WO2013142382A1 (en) 2012-03-22 2013-03-15 Substituted pyridopyrimidine compounds and their use as flt3 inhibitors

Publications (1)

Publication Number Publication Date
SG11201405942RA true SG11201405942RA (en) 2014-10-30

Family

ID=49223277

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201405942RA SG11201405942RA (en) 2012-03-22 2013-03-15 Substituted pyridopyrimidine compounds and their use as flt3 inhibitors

Country Status (22)

Country Link
US (1) US8877763B2 (en)
EP (1) EP2828259B1 (en)
JP (1) JP6101341B2 (en)
KR (1) KR102011770B1 (en)
CN (1) CN104428298B (en)
AU (1) AU2013235344B2 (en)
BR (1) BR112014023460B1 (en)
CA (1) CA2868156C (en)
CL (1) CL2014002505A1 (en)
EA (1) EA031267B1 (en)
ES (1) ES2694223T3 (en)
HK (1) HK1208453A1 (en)
IL (1) IL234802B (en)
IN (1) IN2014MN02082A (en)
MX (1) MX360912B (en)
MY (1) MY184858A (en)
NZ (1) NZ700283A (en)
PL (1) PL2828259T3 (en)
SG (1) SG11201405942RA (en)
TR (1) TR201816480T4 (en)
WO (1) WO2013142382A1 (en)
ZA (1) ZA201407588B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3060562T (en) * 2013-10-21 2021-09-02 Genosco Substituted pyrimidine compounds and their use as syk inhibitors
JP6665154B2 (en) * 2014-07-17 2020-03-13 ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド Substituted urea derivatives and their pharmaceutical use
KR20160035411A (en) * 2014-09-23 2016-03-31 주식회사 오스코텍 Pyridopyrimidine derivatives as lrrk2 (leucine rich repeat kinase 2) inhinitor
KR20170087913A (en) 2014-11-17 2017-07-31 로드아일랜드하스피틀 Nanomaterial compositions, synthesis, and assembly
AU2019292207B2 (en) * 2018-06-27 2022-06-30 Oscotec Inc. Pyridopyrimidinone derivatives for use as Axl inhibitors
KR20200022712A (en) * 2018-08-23 2020-03-04 주식회사 오스코텍 Crystalline form of 8-bromo-2-(1-methylpiperidin-4-ylamino)-4-(4-phenoxyphenylamino)pyrido[4,3-d]pyrimidin-5(6h)-one hydrochloride and preparation method thereof
KR102230721B1 (en) * 2019-02-01 2021-03-22 주식회사 오스코텍 Oral solid formulation comprising pyridopyrimidin-based hydrochloride and preparation method thereof
BR112021018168B1 (en) 2019-03-21 2023-11-28 Onxeo PHARMACEUTICAL COMPOSITION, COMBINATION AND KIT COMPRISING A DBAIT MOLECULE AND A KINASE INHIBITOR FOR THE TREATMENT OF CANCER
CN110327347B (en) * 2019-08-16 2021-06-01 陕西科技大学 Application of G-749 in preparing antifungal medicine
TWI759829B (en) * 2019-08-23 2022-04-01 財團法人生物技術開發中心 Heterocyclic pyrazole derivatives as type iii receptor tyrosine kinase inhibitors
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
TW202340177A (en) 2021-12-30 2023-10-16 美商拜歐米富士恩股份有限公司 Pyrazine compounds as inhibitors of flt3
WO2023225005A1 (en) 2022-05-17 2023-11-23 Biomea Fusion, Inc. Flt3 combination therapy for cancer and compositions therefor
KR102440707B1 (en) 2022-07-10 2022-09-05 이우미 Factory recommendation system

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020070520A (en) * 2000-01-27 2002-09-09 워너-램버트 캄파니 Pyridopyrimidinone Derivatives for Treatment of Neurodegenerative Disease
BR0113628A (en) * 2000-08-31 2003-07-01 Hoffmann La Roche 7-oxopyridopyrimidines as inhibitors of cell proliferation
MXPA03001733A (en) * 2000-08-31 2003-05-27 Hoffmann La Roche 7-oxo pyridopyrimidines.
EP2025678A1 (en) * 2007-08-17 2009-02-18 Oncalis AG Pyrazolo[3,4-d]pyrimidine compounds and their use as modulators of protein kinase
TW200938542A (en) * 2008-02-01 2009-09-16 Irm Llc Compounds and compositions as kinase inhibitors
ES2432414T3 (en) * 2008-08-12 2013-12-03 Glaxosmithkline Llc Chemical compounds
US8338481B2 (en) * 2009-01-28 2012-12-25 Ramot At Tel-Aviv University Ltd. Alkoxyalkyl S-prenylthiosalicylates for treatment of cancer
JP2013502429A (en) * 2009-08-19 2013-01-24 アムビト ビオスシエンセス コルポラチオン Biaryl compounds and methods of use thereof
CN102695416B (en) * 2009-10-29 2017-03-08 金纳斯克公司 Kinase inhibitor

Also Published As

Publication number Publication date
EP2828259A4 (en) 2015-08-19
CN104428298A (en) 2015-03-18
JP6101341B2 (en) 2017-03-22
JP2015510942A (en) 2015-04-13
EA031267B1 (en) 2018-12-28
KR20140144709A (en) 2014-12-19
CN104428298B (en) 2017-03-01
IL234802B (en) 2018-10-31
IN2014MN02082A (en) 2015-08-21
TR201816480T4 (en) 2018-11-21
MY184858A (en) 2021-04-27
US8877763B2 (en) 2014-11-04
AU2013235344B2 (en) 2017-03-16
EP2828259B1 (en) 2018-08-08
EP2828259A1 (en) 2015-01-28
ZA201407588B (en) 2015-11-25
HK1208453A1 (en) 2016-03-04
MX2014011354A (en) 2014-12-05
CA2868156A1 (en) 2013-09-26
CL2014002505A1 (en) 2015-10-02
US20130274274A1 (en) 2013-10-17
AU2013235344A1 (en) 2014-10-09
BR112014023460B1 (en) 2020-09-01
MX360912B (en) 2018-11-22
KR102011770B1 (en) 2019-08-19
CA2868156C (en) 2020-07-28
WO2013142382A1 (en) 2013-09-26
PL2828259T3 (en) 2019-02-28
NZ700283A (en) 2016-08-26
EA201491747A1 (en) 2015-10-30
ES2694223T3 (en) 2018-12-19

Similar Documents

Publication Publication Date Title
HK1208453A1 (en) Substituted pyridopyrimidine compounds and their use as flt3 inhibitors flt3
HRP20151103T1 (en) Substituted triazolopyridines and their use as ttk inhibitors
RS58892B1 (en) 3-aminocycloalkyl compounds as ror-gamma-t inhibitors and uses thereof
AP2015008328A0 (en) Pyrrolotriazinone derivatives as pi3k inhibitors
HK1210771A1 (en) Azaindole derivatives which act as pi3k inhibitors
ZA201406082B (en) Use of ccr3-inhibitors
SG11201503977PA (en) Azaindole derivatives as jak3 inhibitors
HK1206350A1 (en) 2h-imidazol-4-amine compounds and their use as bace inhibitors 2h--4- bace
HK1212331A1 (en) 4-carboxamido-isoindolinone derivatives as selective parp-1 inhibitors parp-1 4--
HK1201270A1 (en) Tetrazol-5-yl- and triazol-5-yl-aryl compounds and use thereof as herbicides -5---5--
HK1208029A1 (en) Imidazopyridine derivatives
IL239245A0 (en) New use of aclidinium
HK1214244A1 (en) Imidazopyridine derivatives
GB201209458D0 (en) Novel compounds and their use as kinase inhibitors
GB201206048D0 (en) Novel compounds and their use as kinase inhibitors
GB201213726D0 (en) Novel compounds and their use